Local Control and Survival Following Concomitant Chemoradiotherapy in Inoperable Stage I Non-Small-Cell Lung Cancer
Purpose Concomitant chemoradiotherapy (CRT) increases survival rates compared with radical radiotherapy alone (RT) in Stage III non-small-cell lung cancer (NSCLC), as a result of improved local control. The effect of CRT on local control in Stage I NSCLC is less well documented. We retrospectively r...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2009-08, Vol.74 (5), p.1371-1375 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1375 |
|---|---|
| container_issue | 5 |
| container_start_page | 1371 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 74 |
| creator | Campeau, Marie-Pierre, M.D Herschtal, Alan, B.Sc.(Hons) Wheeler, Greg, M.B.B.S, F.R.A.N.Z.C.R Mac Manus, Michael, M.D., F.R.C.R Wirth, Andrew, M.B.B.S., F.R.A.C.P., F.R.A.N.Z.C.R Michael, Michael, B.Sc(Hons), M.B.B.S.(Hons), F.R.A.C.P Hogg, Annette, Ph.D Drummond, Elizabeth, M.Sc Ball, David, M.B.B.S., M.D., F.R.A.N.Z.C.R |
| description | Purpose Concomitant chemoradiotherapy (CRT) increases survival rates compared with radical radiotherapy alone (RT) in Stage III non-small-cell lung cancer (NSCLC), as a result of improved local control. The effect of CRT on local control in Stage I NSCLC is less well documented. We retrospectively reviewed local control and survival following CRT or RT for inoperable Stage I NSCLC patients. Methods and materials Eligible patients had histologically/cytologically proved inoperable Stage I NSCLC and had undergone complete staging investigations including an F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scan. Radiotherapy was planned as ( 1 ) 60 Gy in 30 fractions over 6 weeks with or without concomitant chemotherapy or ( 2 ) 50–55 Gy in 20 fractions without chemotherapy. Results Between 2000 and 2005, 73 patients met the eligibility criteria and were treated as follows: CRT (60 Gy)—39; RT (60 Gy)—23; RT (50–55 Gy)—11. The median follow-up time for all patients was 18 months (range, 1–81 months). Survival analysis was based on intent to treat. Local progression-free survival (PFS) at 2 years was 66% with CRT and 55% with RT. The 2-year distant PFS was 60% following CRT and 63% after RT. The 2-year PFS rates were 57% and 50%, respectively. The 2-year survival rate for patients treated with CRT was 57% and 33% in patients receiving RT. Conclusions Despite the use of CRT and routine staging with FDG-PET, both local and distant recurrences remain important causes of treatment failure in patients with inoperable stage I NSCLC. |
| doi_str_mv | 10.1016/j.ijrobp.2008.10.067 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_21276932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301608037164</els_id><sourcerecordid>67499380</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-c9f96547b2fe8f36a1e4f56915e4589aaa269cd0dedbeb8b4a5b1daf9e89a0f43</originalsourceid><addsrcrecordid>eNqFUl2L1DAUDaK4s6v_QCQg-NYxadOPvAhSdt2BQR9GwbeQprc7qWkyJunI_HtTOiD44lPIveeenJxzEXpDyZYSWn0Yt3r0rjttc0KaVNqSqn6GNrSpeVaU5Y_naEOKimRFAt-g2xBGQgilNXuJbijPS1JXfIPC3ilpcOts9M5gaXt8mP1Zn1PxwRnjfmv7tLSVm3SUNuL2CJPzstcuHsHL0wVri3fWndKlM4APUT4B3uEvzmaHSRqTtWAM3s8Lj7QK_Cv0YpAmwOvreYe-P9x_ax-z_dfPu_bTPlOMFTFTfOBVyeouH6AZikpSYENZcVoCKxsupcwrrnrSQ99B13RMlh3t5cAhNcnAijv0buV1IWoRlI6gjspZCyqKnObJgCJPqPcr6uTdrxlCFJMOKkmWFtwcRFUzzouGJCBbgcq7EDwM4uT1JP1FUCKWSMQo1kjEEslSTZGksbdX_rmboP87dM0gAT6uAEhenDX4RSoko3rtF6W90_974V8CZbTVKdefcIEwutnb5LOgIuSCiMOyFstWkPSpmlas-AN6ObUc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67499380</pqid></control><display><type>article</type><title>Local Control and Survival Following Concomitant Chemoradiotherapy in Inoperable Stage I Non-Small-Cell Lung Cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Campeau, Marie-Pierre, M.D ; Herschtal, Alan, B.Sc.(Hons) ; Wheeler, Greg, M.B.B.S, F.R.A.N.Z.C.R ; Mac Manus, Michael, M.D., F.R.C.R ; Wirth, Andrew, M.B.B.S., F.R.A.C.P., F.R.A.N.Z.C.R ; Michael, Michael, B.Sc(Hons), M.B.B.S.(Hons), F.R.A.C.P ; Hogg, Annette, Ph.D ; Drummond, Elizabeth, M.Sc ; Ball, David, M.B.B.S., M.D., F.R.A.N.Z.C.R</creator><creatorcontrib>Campeau, Marie-Pierre, M.D ; Herschtal, Alan, B.Sc.(Hons) ; Wheeler, Greg, M.B.B.S, F.R.A.N.Z.C.R ; Mac Manus, Michael, M.D., F.R.C.R ; Wirth, Andrew, M.B.B.S., F.R.A.C.P., F.R.A.N.Z.C.R ; Michael, Michael, B.Sc(Hons), M.B.B.S.(Hons), F.R.A.C.P ; Hogg, Annette, Ph.D ; Drummond, Elizabeth, M.Sc ; Ball, David, M.B.B.S., M.D., F.R.A.N.Z.C.R</creatorcontrib><description>Purpose Concomitant chemoradiotherapy (CRT) increases survival rates compared with radical radiotherapy alone (RT) in Stage III non-small-cell lung cancer (NSCLC), as a result of improved local control. The effect of CRT on local control in Stage I NSCLC is less well documented. We retrospectively reviewed local control and survival following CRT or RT for inoperable Stage I NSCLC patients. Methods and materials Eligible patients had histologically/cytologically proved inoperable Stage I NSCLC and had undergone complete staging investigations including an F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scan. Radiotherapy was planned as ( 1 ) 60 Gy in 30 fractions over 6 weeks with or without concomitant chemotherapy or ( 2 ) 50–55 Gy in 20 fractions without chemotherapy. Results Between 2000 and 2005, 73 patients met the eligibility criteria and were treated as follows: CRT (60 Gy)—39; RT (60 Gy)—23; RT (50–55 Gy)—11. The median follow-up time for all patients was 18 months (range, 1–81 months). Survival analysis was based on intent to treat. Local progression-free survival (PFS) at 2 years was 66% with CRT and 55% with RT. The 2-year distant PFS was 60% following CRT and 63% after RT. The 2-year PFS rates were 57% and 50%, respectively. The 2-year survival rate for patients treated with CRT was 57% and 33% in patients receiving RT. Conclusions Despite the use of CRT and routine staging with FDG-PET, both local and distant recurrences remain important causes of treatment failure in patients with inoperable stage I NSCLC.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2008.10.067</identifier><identifier>PMID: 19250769</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma - radiotherapy ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carboplatin - administration & dosage ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - radiotherapy ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - radiotherapy ; Chemoradiation ; CHEMOTHERAPY ; Combined Modality Therapy - methods ; COMBINED THERAPY ; Disease Progression ; Dose Fractionation ; Early-stage ; Female ; FLUORINE 18 ; FLUORODEOXYGLUCOSE ; Hematology, Oncology and Palliative Medicine ; Humans ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Lung Neoplasms - radiotherapy ; LUNGS ; Male ; Medically inoperable ; Middle Aged ; Neoplasm Staging ; NEOPLASMS ; Paclitaxel - administration & dosage ; PATIENTS ; POSITRON COMPUTED TOMOGRAPHY ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Radiotherapy, Conformal ; Regression Analysis ; Retrospective Studies ; Survival Rate ; Taxoids - administration & dosage ; Three-dimensional conformal radiation therapy</subject><ispartof>International journal of radiation oncology, biology, physics, 2009-08, Vol.74 (5), p.1371-1375</ispartof><rights>2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-c9f96547b2fe8f36a1e4f56915e4589aaa269cd0dedbeb8b4a5b1daf9e89a0f43</citedby><cites>FETCH-LOGICAL-c443t-c9f96547b2fe8f36a1e4f56915e4589aaa269cd0dedbeb8b4a5b1daf9e89a0f43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0360301608037164$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19250769$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/21276932$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Campeau, Marie-Pierre, M.D</creatorcontrib><creatorcontrib>Herschtal, Alan, B.Sc.(Hons)</creatorcontrib><creatorcontrib>Wheeler, Greg, M.B.B.S, F.R.A.N.Z.C.R</creatorcontrib><creatorcontrib>Mac Manus, Michael, M.D., F.R.C.R</creatorcontrib><creatorcontrib>Wirth, Andrew, M.B.B.S., F.R.A.C.P., F.R.A.N.Z.C.R</creatorcontrib><creatorcontrib>Michael, Michael, B.Sc(Hons), M.B.B.S.(Hons), F.R.A.C.P</creatorcontrib><creatorcontrib>Hogg, Annette, Ph.D</creatorcontrib><creatorcontrib>Drummond, Elizabeth, M.Sc</creatorcontrib><creatorcontrib>Ball, David, M.B.B.S., M.D., F.R.A.N.Z.C.R</creatorcontrib><title>Local Control and Survival Following Concomitant Chemoradiotherapy in Inoperable Stage I Non-Small-Cell Lung Cancer</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose Concomitant chemoradiotherapy (CRT) increases survival rates compared with radical radiotherapy alone (RT) in Stage III non-small-cell lung cancer (NSCLC), as a result of improved local control. The effect of CRT on local control in Stage I NSCLC is less well documented. We retrospectively reviewed local control and survival following CRT or RT for inoperable Stage I NSCLC patients. Methods and materials Eligible patients had histologically/cytologically proved inoperable Stage I NSCLC and had undergone complete staging investigations including an F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scan. Radiotherapy was planned as ( 1 ) 60 Gy in 30 fractions over 6 weeks with or without concomitant chemotherapy or ( 2 ) 50–55 Gy in 20 fractions without chemotherapy. Results Between 2000 and 2005, 73 patients met the eligibility criteria and were treated as follows: CRT (60 Gy)—39; RT (60 Gy)—23; RT (50–55 Gy)—11. The median follow-up time for all patients was 18 months (range, 1–81 months). Survival analysis was based on intent to treat. Local progression-free survival (PFS) at 2 years was 66% with CRT and 55% with RT. The 2-year distant PFS was 60% following CRT and 63% after RT. The 2-year PFS rates were 57% and 50%, respectively. The 2-year survival rate for patients treated with CRT was 57% and 33% in patients receiving RT. Conclusions Despite the use of CRT and routine staging with FDG-PET, both local and distant recurrences remain important causes of treatment failure in patients with inoperable stage I NSCLC.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma - radiotherapy</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - radiotherapy</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>Chemoradiation</subject><subject>CHEMOTHERAPY</subject><subject>Combined Modality Therapy - methods</subject><subject>COMBINED THERAPY</subject><subject>Disease Progression</subject><subject>Dose Fractionation</subject><subject>Early-stage</subject><subject>Female</subject><subject>FLUORINE 18</subject><subject>FLUORODEOXYGLUCOSE</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>LUNGS</subject><subject>Male</subject><subject>Medically inoperable</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>NEOPLASMS</subject><subject>Paclitaxel - administration & dosage</subject><subject>PATIENTS</subject><subject>POSITRON COMPUTED TOMOGRAPHY</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Radiotherapy, Conformal</subject><subject>Regression Analysis</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Taxoids - administration & dosage</subject><subject>Three-dimensional conformal radiation therapy</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUl2L1DAUDaK4s6v_QCQg-NYxadOPvAhSdt2BQR9GwbeQprc7qWkyJunI_HtTOiD44lPIveeenJxzEXpDyZYSWn0Yt3r0rjttc0KaVNqSqn6GNrSpeVaU5Y_naEOKimRFAt-g2xBGQgilNXuJbijPS1JXfIPC3ilpcOts9M5gaXt8mP1Zn1PxwRnjfmv7tLSVm3SUNuL2CJPzstcuHsHL0wVri3fWndKlM4APUT4B3uEvzmaHSRqTtWAM3s8Lj7QK_Cv0YpAmwOvreYe-P9x_ax-z_dfPu_bTPlOMFTFTfOBVyeouH6AZikpSYENZcVoCKxsupcwrrnrSQ99B13RMlh3t5cAhNcnAijv0buV1IWoRlI6gjspZCyqKnObJgCJPqPcr6uTdrxlCFJMOKkmWFtwcRFUzzouGJCBbgcq7EDwM4uT1JP1FUCKWSMQo1kjEEslSTZGksbdX_rmboP87dM0gAT6uAEhenDX4RSoko3rtF6W90_974V8CZbTVKdefcIEwutnb5LOgIuSCiMOyFstWkPSpmlas-AN6ObUc</recordid><startdate>20090801</startdate><enddate>20090801</enddate><creator>Campeau, Marie-Pierre, M.D</creator><creator>Herschtal, Alan, B.Sc.(Hons)</creator><creator>Wheeler, Greg, M.B.B.S, F.R.A.N.Z.C.R</creator><creator>Mac Manus, Michael, M.D., F.R.C.R</creator><creator>Wirth, Andrew, M.B.B.S., F.R.A.C.P., F.R.A.N.Z.C.R</creator><creator>Michael, Michael, B.Sc(Hons), M.B.B.S.(Hons), F.R.A.C.P</creator><creator>Hogg, Annette, Ph.D</creator><creator>Drummond, Elizabeth, M.Sc</creator><creator>Ball, David, M.B.B.S., M.D., F.R.A.N.Z.C.R</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20090801</creationdate><title>Local Control and Survival Following Concomitant Chemoradiotherapy in Inoperable Stage I Non-Small-Cell Lung Cancer</title><author>Campeau, Marie-Pierre, M.D ; Herschtal, Alan, B.Sc.(Hons) ; Wheeler, Greg, M.B.B.S, F.R.A.N.Z.C.R ; Mac Manus, Michael, M.D., F.R.C.R ; Wirth, Andrew, M.B.B.S., F.R.A.C.P., F.R.A.N.Z.C.R ; Michael, Michael, B.Sc(Hons), M.B.B.S.(Hons), F.R.A.C.P ; Hogg, Annette, Ph.D ; Drummond, Elizabeth, M.Sc ; Ball, David, M.B.B.S., M.D., F.R.A.N.Z.C.R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-c9f96547b2fe8f36a1e4f56915e4589aaa269cd0dedbeb8b4a5b1daf9e89a0f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma - radiotherapy</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - radiotherapy</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>Chemoradiation</topic><topic>CHEMOTHERAPY</topic><topic>Combined Modality Therapy - methods</topic><topic>COMBINED THERAPY</topic><topic>Disease Progression</topic><topic>Dose Fractionation</topic><topic>Early-stage</topic><topic>Female</topic><topic>FLUORINE 18</topic><topic>FLUORODEOXYGLUCOSE</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>LUNGS</topic><topic>Male</topic><topic>Medically inoperable</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>NEOPLASMS</topic><topic>Paclitaxel - administration & dosage</topic><topic>PATIENTS</topic><topic>POSITRON COMPUTED TOMOGRAPHY</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Radiotherapy, Conformal</topic><topic>Regression Analysis</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Taxoids - administration & dosage</topic><topic>Three-dimensional conformal radiation therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Campeau, Marie-Pierre, M.D</creatorcontrib><creatorcontrib>Herschtal, Alan, B.Sc.(Hons)</creatorcontrib><creatorcontrib>Wheeler, Greg, M.B.B.S, F.R.A.N.Z.C.R</creatorcontrib><creatorcontrib>Mac Manus, Michael, M.D., F.R.C.R</creatorcontrib><creatorcontrib>Wirth, Andrew, M.B.B.S., F.R.A.C.P., F.R.A.N.Z.C.R</creatorcontrib><creatorcontrib>Michael, Michael, B.Sc(Hons), M.B.B.S.(Hons), F.R.A.C.P</creatorcontrib><creatorcontrib>Hogg, Annette, Ph.D</creatorcontrib><creatorcontrib>Drummond, Elizabeth, M.Sc</creatorcontrib><creatorcontrib>Ball, David, M.B.B.S., M.D., F.R.A.N.Z.C.R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Campeau, Marie-Pierre, M.D</au><au>Herschtal, Alan, B.Sc.(Hons)</au><au>Wheeler, Greg, M.B.B.S, F.R.A.N.Z.C.R</au><au>Mac Manus, Michael, M.D., F.R.C.R</au><au>Wirth, Andrew, M.B.B.S., F.R.A.C.P., F.R.A.N.Z.C.R</au><au>Michael, Michael, B.Sc(Hons), M.B.B.S.(Hons), F.R.A.C.P</au><au>Hogg, Annette, Ph.D</au><au>Drummond, Elizabeth, M.Sc</au><au>Ball, David, M.B.B.S., M.D., F.R.A.N.Z.C.R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Local Control and Survival Following Concomitant Chemoradiotherapy in Inoperable Stage I Non-Small-Cell Lung Cancer</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2009-08-01</date><risdate>2009</risdate><volume>74</volume><issue>5</issue><spage>1371</spage><epage>1375</epage><pages>1371-1375</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose Concomitant chemoradiotherapy (CRT) increases survival rates compared with radical radiotherapy alone (RT) in Stage III non-small-cell lung cancer (NSCLC), as a result of improved local control. The effect of CRT on local control in Stage I NSCLC is less well documented. We retrospectively reviewed local control and survival following CRT or RT for inoperable Stage I NSCLC patients. Methods and materials Eligible patients had histologically/cytologically proved inoperable Stage I NSCLC and had undergone complete staging investigations including an F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scan. Radiotherapy was planned as ( 1 ) 60 Gy in 30 fractions over 6 weeks with or without concomitant chemotherapy or ( 2 ) 50–55 Gy in 20 fractions without chemotherapy. Results Between 2000 and 2005, 73 patients met the eligibility criteria and were treated as follows: CRT (60 Gy)—39; RT (60 Gy)—23; RT (50–55 Gy)—11. The median follow-up time for all patients was 18 months (range, 1–81 months). Survival analysis was based on intent to treat. Local progression-free survival (PFS) at 2 years was 66% with CRT and 55% with RT. The 2-year distant PFS was 60% following CRT and 63% after RT. The 2-year PFS rates were 57% and 50%, respectively. The 2-year survival rate for patients treated with CRT was 57% and 33% in patients receiving RT. Conclusions Despite the use of CRT and routine staging with FDG-PET, both local and distant recurrences remain important causes of treatment failure in patients with inoperable stage I NSCLC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>19250769</pmid><doi>10.1016/j.ijrobp.2008.10.067</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2009-08, Vol.74 (5), p.1371-1375 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_osti_scitechconnect_21276932 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - radiotherapy Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - radiotherapy Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - radiotherapy Chemoradiation CHEMOTHERAPY Combined Modality Therapy - methods COMBINED THERAPY Disease Progression Dose Fractionation Early-stage Female FLUORINE 18 FLUORODEOXYGLUCOSE Hematology, Oncology and Palliative Medicine Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - radiotherapy LUNGS Male Medically inoperable Middle Aged Neoplasm Staging NEOPLASMS Paclitaxel - administration & dosage PATIENTS POSITRON COMPUTED TOMOGRAPHY Radiology RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Radiotherapy, Conformal Regression Analysis Retrospective Studies Survival Rate Taxoids - administration & dosage Three-dimensional conformal radiation therapy |
| title | Local Control and Survival Following Concomitant Chemoradiotherapy in Inoperable Stage I Non-Small-Cell Lung Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A30%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Local%20Control%20and%20Survival%20Following%20Concomitant%20Chemoradiotherapy%20in%20Inoperable%20Stage%20I%20Non-Small-Cell%20Lung%20Cancer&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Campeau,%20Marie-Pierre,%20M.D&rft.date=2009-08-01&rft.volume=74&rft.issue=5&rft.spage=1371&rft.epage=1375&rft.pages=1371-1375&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2008.10.067&rft_dat=%3Cproquest_osti_%3E67499380%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67499380&rft_id=info:pmid/19250769&rft_els_id=S0360301608037164&rfr_iscdi=true |